Heart failure with preserved ejection fraction: Pathophysiology, diagnosis, and treatment

Barry A Borlaug, Walter J. Paulus

Research output: Contribution to journalArticle

575 Citations (Scopus)

Abstract

Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF). Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified. While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute. Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment. In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.

Original languageEnglish (US)
Pages (from-to)670-679
Number of pages10
JournalEuropean Heart Journal
Volume32
Issue number6
DOIs
StatePublished - Mar 2011

Fingerprint

Heart Failure
Cardiovascular Abnormalities
Stroke Volume
Hemodynamics
Clinical Trials
Morbidity
Mortality
Therapeutics
Research

Keywords

  • Diagnosis
  • Diastolic
  • Ejection fraction
  • Heart failure
  • Pathophysiology
  • Preserved ejection fraction
  • Systolic
  • Treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Heart failure with preserved ejection fraction : Pathophysiology, diagnosis, and treatment. / Borlaug, Barry A; Paulus, Walter J.

In: European Heart Journal, Vol. 32, No. 6, 03.2011, p. 670-679.

Research output: Contribution to journalArticle

@article{8096b483a0df4cd8827324192403b3d2,
title = "Heart failure with preserved ejection fraction: Pathophysiology, diagnosis, and treatment",
abstract = "Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF). Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified. While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute. Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment. In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.",
keywords = "Diagnosis, Diastolic, Ejection fraction, Heart failure, Pathophysiology, Preserved ejection fraction, Systolic, Treatment",
author = "Borlaug, {Barry A} and Paulus, {Walter J.}",
year = "2011",
month = "3",
doi = "10.1093/eurheartj/ehq426",
language = "English (US)",
volume = "32",
pages = "670--679",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Heart failure with preserved ejection fraction

T2 - Pathophysiology, diagnosis, and treatment

AU - Borlaug, Barry A

AU - Paulus, Walter J.

PY - 2011/3

Y1 - 2011/3

N2 - Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF). Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified. While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute. Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment. In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.

AB - Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF). Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified. While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute. Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment. In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.

KW - Diagnosis

KW - Diastolic

KW - Ejection fraction

KW - Heart failure

KW - Pathophysiology

KW - Preserved ejection fraction

KW - Systolic

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=79952829685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952829685&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehq426

DO - 10.1093/eurheartj/ehq426

M3 - Article

C2 - 21138935

AN - SCOPUS:79952829685

VL - 32

SP - 670

EP - 679

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 6

ER -